Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Other serious adverse events · people with osteoporotic vertebral compression fracture
The intervention showed no clear difference in other serious adverse events (low certainty).
1 finding from 1 review
Adverse events: atonic pupil · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in adverse events: atonic pupil compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ hepatopathy · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention showed no clear difference in adverse events ‐ hepatopathy (low certainty).
1 finding from 1 review
Adverse events (hot flushes) · women with uterine fibroids
GnRHa treatment may leads to higher adverse events (hot flushes) compared with other medical therapies before any surgery (low certainty).
1 finding from 1 review
SAEs · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
1 finding from 1 review
Adverse events: hypertension · kidney transplant recipients
Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).
1 finding from 1 review
RR 0.82 [0.71, 0.95]
950 participants
Low
Paraesthesia · patients undergoing lumbar punctures with atraumatic needles (Whitacre, Atraucan, Sprotte, Cappe‐Deutsh, Pajunk, Gertie Marx, Durasafe,…
Larger atraumatic needles probably leads to lower adverse events: paraesthesia compared with smaller atraumatic needles (moderate certainty).
1 finding from 1 review
Paraesthesia · participants undergoing lumbar puncture
Traumatic needles showed no clear difference in adverse events: paraesthesia compared with atraumatic needles (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
1 finding from 1 review